XableCath, a Salt Lake City company, won FDA clearance for its XableCath blunt tip support catheter for crossing calcified lesions in the peripheral vasculature both above and below the knee. It results in a tunnel through the lesion, helping to facilitate the placement of stents or other therapies.
“In two clinical investigator-led studies, XableCath was demonstrated to be a safe, effective, and easy-to-use device, enabling therapeutic options for patients with PAD,” in a published statement said Johannes Dahm, M.D., Director of Interventional Cardiology & Angiology, Heart & Vascular Center Neu-Bethlehem, Göttingen, Germany. “The XableCath blunt tip catheter is unique in its ability to cross chronic total occlusions quickly while remaining over-the-wire and in the true lumen. ”
The device is offered in six size combinations with width ranging from .014″ to .035″ and lengths from 65 cm to 145 cm.
Link: XableCath catheters…